P2P, or not P2P, that is the question
As the 16 January, 2015 deadline for responding to the controversial P2P draft report draws near, and in the interests of balance and representing the whole community, Phoenix Rising presents two differing views on how to react. Today, Clark Ellis flags up important content to...
Discuss the article on the Forums.

Borody 2012: The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherap

Discussion in 'General ME/CFS News' started by Sasha, Mar 1, 2013.

  1. Sasha

    Sasha Fine, thank you

    Messages:
    9,214
    Likes:
    8,883
    UK
    Just seen this on the MEA's weekly research round-up. Impressive results but why have they taken 20 years to publish? Have I misunderstood that?

    http://search.informit.com.au/documentSummary;dn=119626231492520;res=IELHEA
    Journal of the Australasian College of Nutritional and Environmental Medicine, 3 December 2012.
    The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy
    Borody, Thomas J(1); Nowak, Anna(2); Finlayson, Sarah(3)
    (1) Director, Centre for Digestive Diseases, Five Dock NSW 2046, Australia
    (2) Research Assistant, Centre for Digestive Diseases, Five Dock NSW 2046, Australia
    (3) Research Assistant, Centre for Digestive Diseases, Five Dock NSW 2046, Australia

    Abstract
    INTRODUCTION
    Chronic Fatigue Syndrome (CFS) has a complex and multifactorial etiology making treatment and definitive diagnosis, currently made through exclusion, difficult. Current therapies, such as cognitive behaviour therapy and graded exercises, are inadequate and targeted to address symptoms, rather than the underlying disease pathology. Increasing evidence implicates the microbiota of the gut in a number of conditions previously thought distinct from the gastrointestinal system. Previous work with bacteriotherapy in CFS has suggested a link between the condition and the composition and health of the gut microbiota. Here, we review and further examine a larger cohort of CFS patients who had undergone bacteriotherapy for their CFS.
    METHOD
    A total of 60 patients from the Centre for Digestive Diseases presented with CFS. Of these, 52 patients had concurrent IBS and 4 patients additionally had constipation. All underwent initial transcolonoscopic infusion of 13 non-pathogenic enteric bacteria. 52/60 patients undertook an additional rectal infusion a day later and 3/60 undertook an additional 2 rectal infusions.
    RESULTS
    35/60 patients who underwent initial bacteriotherapy responded to treatment. 10/15 patients who failed this course were offered a secondary transcolonoscopic infusion followed by a rectal infusion or an oral course of cultured bacteria. Of these 7/10 responded, giving a total of 42/60 (70%) patients who responded to treatment. Contact was achieved with 12 patients after 15-20 year follow-up.
    Complete resolution of symptoms was maintained in seven of the twelve patients and 5/12 did not experience recurrence for approximately 1.5-3 years post bacteriotherapy.
    CONCLUSION
    Bacteriotherapy achieves initial success rate of 70% in CFS and a 58% sustained response. Given that manipulation of the colonic microbiota improved CFS symptoms, bacteriotherapy for CFS warrants further investigation and may provide further insight into a
    possible etiology of CFS.
     
    justy, Little Bluestem and merylg like this.
  2. Valentijn

    Valentijn Activity Level: 3

    Messages:
    6,968
    Likes:
    10,825
    Amersfoort, Netherlands
    The current publication might just be a follow-up study ... without full access, it's hard to tell.
     
  3. user9876

    user9876 Senior Member

    Messages:
    845
    Likes:
    2,109

See more popular forum discussions.

Share This Page